Table 3.
Clinicopathological characteristics, treatment, and clinical outcomes of patients assessed in the 26 index studies
| Author (country) | Treatment | Number of patients | Mean age (years) | MST (months) | OS rate (%) | IM (%)/MST (months) | VI (%)/MST (months) | LM (%)/MST (months) | |
|---|---|---|---|---|---|---|---|---|---|
| 3y | 5y | ||||||||
| Uenishi et al. [18] 2014 (Japan) | SR | 233 | - | 23.8 | 39 | 31 | 28/12.5 | 72/17.2 | 37/14.3 |
| Igami et al. [19] 2011 (Japan) | SR | 61 | 61 | 24.6 | - | 34 | 31/- | 98/- | 38/- |
| Nakagohri et al. [13] 2008 (Japan) | SR | 56 | 66 | 22 | 42 | 32 | 18/- | -/- | 38/- |
| Luo et al. [20] 2014 (China) | SR | 1333 | 54 | 14.4 | 25 | 17 | 36/10 | 15/14 | 28/9 |
| Wang et al. [21] 2013 (China) | SR | 367 | 53 a | 21 | 41 | 35 | -/- | 15/- | 22/- |
| Li et al. [22] 2011 (China) | SR | 113 | - | 21 | 27 | 17 | 28/- | 22/- | 27/- |
| Jiang et al. [7] 2011 (China) | SR | 344 | - | 17.6 | 32 | 21 | 25/12.3 | 17/11.4 | -/- |
| Cho et al. [23] 2010 (Korea) | SR | 63 | 61 | 25.5 | 51 | 32 | 32/14.5 | -/- | 30/5 |
| Choi et al. [24] 2009 (Korea) | SR | 64 | 61 | 39 | 53 | 40 | 11/- | 58/- | 27/- |
| Paik et al. [25] 2008 (Korea) | SR | 97 | 57 | 53 | 53 | 31 | 10/9.5 | -/- | 24/6.5 |
| Bhudhisawasdi [26] 2012 (Thailand) | SR | 171 | 56 | 7.6 | 19 | 13 | 37/- | 85/- | -/- |
| Ribero et al. [4] 2012 (Italy) | SR | 434 | 65a | 33 | 47 | 33 | 32/- | 53/- | 26/- |
| Guglielmi et al. [27] 2009 (Italy) | SR | 52 | 66 | 40 | 50 | 20 | 21/24 | -/17 | 27/19 |
| Lang et al. [28] 2009 (Germany) | SR | 83 | - | 26 | 38 | 21 | 42/- | 41/- | 34/- |
| Farges et al. [5] 2011 (France) | SR | 212 | 63 | 28 | 43 | 28 | 59/21 | 44/22 | 37/15 |
| Tamandl et al. [29] 2009 (Austria) | SR | 69 | - | 25.5 | 35 | - | 29/- | 18/- | 19/- |
| Hyder et al. [30] 2014 (US) | SR | 514 | 59 a | 38.8 | 52 | 40 | 25/- | 24/- | 18/- |
| Fisher et al. [31] 2012 (US) | SR | 58 | 66 a | 23 | - | - | 21/- | 40/9.6 | 34/10.7 |
| Endo et al. [32] 2008 (US) | SR | 82 | - | 36 | - | - | 35/8 | 32/13 | 9/7 |
| Spolverato et al. [33] 2014 (MN) | SR | 557 | 60a | 26.9 | 38 | 23 | -/- | 39/- | 21/- |
| de Jong et al. [6] 2011 (MN) | SR | 449 | 61a | 27.3 | 44 | 31 | 27/19 | 31/20.0 | 30/22.9 |
| Park et al. [34] 2010 (Korea) | IAT | 72 | 64 | 12.2 | - | - | 57/1 | -/- | -/- |
| Vogl et al. [35] 2012 (Germany) | IAT | 115 | 60 | 13 | 10 | - | 70/- | -/- | -/- |
| Hyder et al. [36] 2013 (US) | IAT | 198 | 61 a | 13.2 | 22 | 16 | 53/- | 10/- | 11/- |
| Chen et al. [37] 2010 (China) | RT | 84 | - | 6.8 | - | - | 25/5.2 | -/- | 85/5.9 |
| Kim et al. [14] 2013 (Korea) | CT | 67 | 58a | 6.2 | - | - | 60/- | -/- | 82/- |
a
Age was described as median age. MST=median survival time; 3y=3 year; 5y=5 year; SR=surgical resection; MN=multinational; IAT=intra-arterial therapy; RT=radiotherapy; CT=chemotherapy.